Andexanet alfa for reversing anticoagulation: Final appraisal document

National Institute for Health and Care Excellence
In DRAFT guidance, NICE recommends andexanet alfa as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the gastrointestinal tract, if the company provides it according to the commercial arrangement.

MHRA reports latest Yellow Card reporting data on blood clots in recipients of Covid-19 vaccines

Medicines and Healthcare products Regulatory Agency
As of 24 March, the MHRA received 22 reports of cerebral venous sinus thrombosis and 8 reports of other thrombosis events with low platelets, out of a total of 18.1 million doses of COVID-19 Vaccine AstraZeneca. The benefits of Covid-19 vaccines continue to outweigh any risks.

Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery: A Scientific Statement From the American Heart Association/American Stroke Association

Circulation
This scientific statement summarises established risk factors for perioperative stroke, preoperative & intraoperative strategies to mitigate risk of stroke, suggestions for postop assessments, & treatment approaches for minimising permanent neurological dysfunction in this group.

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

European Heart Journal
Recommendations of latest 2017 ESC/EACTS guidelines are mostly based on expert opinion. This viewpoint provides updated therapeutic insights on antithrombotic treatment during and after transcatheter aortic valve implantation, based on recent studies and RCTs.

JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021

Joint Committee on Vaccination and Immunisation
JCVI has advised that it is preferable for adults aged <30 years without underlying health conditions that put them at higher risk of severe COVID-19 disease, to be offered an alternative COVID-19 vaccine, if available.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services